Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 14
Key development milestones reached
Diabetes
•
Results from onset 5 phase 3b trial with FiaspⓇ compared to NovoRapidⓇ in adults with type 1 diabetes
DUAL II Japan phase 3a trial with XultophyⓇ completed
Data from the DEVOTE trial submitted for inclusion in the TresibaⓇ label in Japan
Update to the XultophyⓇ label based on LEADER and DEVOTE data submitted in the EU
Phase 3b trial with Victoza® 1.8 mg in Japanese people with type 2 diabetes successfully completed
Obesity
•
Data from LEADER study submitted for inclusion in the SaxendaⓇ label in the USA
Biopharm
changing
diabetes
Recruitment of people with haemophilia A for the phase trial explorer 5 with concizumab completed
novo nordiskView entire presentation